Skip to main content
RNXT
NASDAQ Life Sciences

RenovoRx 将RenovoCath的癌症中心采用率提高三倍，并任命执行董事长以推动商业增长

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$0.938
Mkt Cap
$31.702M
52W Low
$0.701
52W High
$1.45
Market data snapshot near publication time

summarizeSummary

RenovoRx 报告其获得FDA批准的RenovoCath设备的商业动力明显，过去一年中其活跃的美国癌症中心数量增加三倍，达到12个，其销售管道增加到33个中心。自获得批准以来，公司已完成超过700例成功的程序，随着重复购买订单的增加，表明医生对产品的满意度很高。为了进一步加速采用，公司创始人和首席医疗官Ramtin Agah博士被任命为执行董事长的额外职位。这一进展表明临床需求日益增长，并为公司在2026年全年实现潜在的收入扩张做好了准备，战略性领导层变动凸显了对商业执行的强烈关注。

在该公告发布时，RNXT的交易价格为$0.94，交易所为NASDAQ，所属行业为Life Sciences，市值约为$3170.2万。 52周交易区间为$0.70至$1.45。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed RNXT - Latest Insights

RNXT
Apr 27, 2026, 5:20 PM EDT
Filing Type: 424B3
Importance Score:
8
RenovoRx Registers Resale of 15.9 Million Shares from Recent Private Placement, Creating Significant Market Overhang
Sentiment: Negative
View Wiseek Article
RNXT
Apr 16, 2026, 5:10 PM EDT
Filing Type: S-3
Importance Score:
8
RenovoRx Registers Over $20 Million in Shares and Warrants for Resale by Private Placement Investors
Sentiment: Negative
View Wiseek Article
RNXT
Apr 08, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
RenovoCath Device Secures First Japanese Patent Allowance, Bolstering Global IP and Asia Expansion
Sentiment: Positive
View Wiseek Article
RNXT
Mar 30, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
RenovoRx Reports $1.1M RenovoCath Revenue in First Full Year, Confirms Strong Cash Position & Trial Progress
Sentiment: Positive
View Wiseek Article
RNXT
Mar 27, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
RenovoRx Appoints Dr. Ramtin Agah as Executive Chairman with $450K Base Salary and Bonus Eligibility
Sentiment: Positive
View Wiseek Article
RNXT
Mar 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
RenovoRx's TIGeR-PaC Phase III Trial Surpasses 100 Patients, Nears Enrollment Completion
Sentiment: Positive
View Wiseek Article
RNXT
Mar 24, 2026, 9:16 PM EDT
Filing Type: 4
Importance Score:
7
RenovoRx CEO Invests $27,702 in Company's Recently Closed Private Placement
Sentiment: Positive
View Wiseek Article
RNXT
Mar 24, 2026, 9:15 PM EDT
Filing Type: 4
Importance Score:
8
CFO Mark Voll Invests $110,808 in RenovoRx Through Private Placement, Acquiring Stock and Warrants
Sentiment: Positive
View Wiseek Article
RNXT
Mar 23, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
RenovoRx Secures $10M Private Placement to Fund Commercialization and Phase III Trial
Sentiment: Positive
View Wiseek Article
RNXT
Mar 18, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
8
RenovoRx Secures $10M Private Placement, Issuing ~10.6M Shares and Warrants
Sentiment: Neutral
View Wiseek Article